Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons

Abstract Background Janus kinase (JAK) inhibitors, such as baricitinib, are widely used to treat rheumatoid arthritis (RA). Clinical studies show that baricitinib is more effective at reducing pain than other similar drugs. Here, we aimed to elucidate the molecular mechanisms underlying the pain rel...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Kenta Makabe, Hiroyuki Okada, Naohiro Tachibana, Hisatoshi Ishikura, Norihito Ito, Masaru Tanaka, Ryota Chijimatsu, Asuka Terashima, Fumiko Yano, Meiko Asaka, Dai Yanagihara, Shuji Taketomi, Takumi Matsumoto, Sakae Tanaka, Yasunori Omata, Taku Saito
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2024-06-01
Sarja:	Arthritis Research & Therapy
Aiheet:	Rheumatoid arthritis Pain-related behaviour CAIA model Baricitinib JAK/STAT3 pathway
Linkit:	https://doi.org/10.1186/s13075-024-03354-1
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!